For the quarter ending 2026-03-31, IMDX has $40,427K in assets. $51,118K in debts. $28,201K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 28,201 | 11,583 | 18,692 | 24,287 |
| Accounts receivable, net of allowance for credit losses of 2 and 11, respectively | 157 | 1,128 | 258 | 512 |
| Inventories | 382 | 446 | 471 | 693 |
| Deferred financing costs | - | 0 | - | - |
| Intangible assets, net | - | 0 | 14,600 | 14,600 |
| Restricted cash, current | 729 | 729 | 729 | - |
| Prepaid expenses and other current assets | 1,048 | 1,420 | 1,239 | 1,350 |
| Total current assets | 30,517 | 15,306 | 21,389 | 26,842 |
| Right-of-use and financing lease assets, net | - | - | 2,340 | 2,524 |
| Right-of-use operating and financing lease assets, net | 2,459 | 2,815 | - | - |
| Machinery and equipment, net, and construction in progress | 6,452 | 6,435 | 4,147 | 4,149 |
| Restricted cash, noncurrent | 425 | 607 | 789 | 1,700 |
| Other noncurrent assets | 574 | 593 | 672 | 702 |
| Total assets | 40,427 | 25,756 | 43,937 | 50,517 |
| Accounts payable | 1,615 | 2,544 | 1,056 | 1,277 |
| Due to related party (note 9) | 2,736 | 2,780 | - | - |
| Accrued compensation | 3,333 | 2,461 | 2,228 | 1,459 |
| Accrued royalties | 1,116 | 1,116 | 1,120 | 1,116 |
| Accrued expenses and other current liabilities | 1,284 | 939 | 602 | 571 |
| Right-of-use and financing lease liabilities, current | - | - | 1,598 | 1,540 |
| Operating and financing lease liabilities, current | 1,762 | 1,807 | - | - |
| Contingent consideration liabilities, current | 159 | 428 | 1,056 | 689 |
| Total current liabilities | 12,005 | 12,075 | 7,660 | 6,652 |
| Right-of-use and financing lease liabilities, noncurrent | - | - | 1,529 | 1,834 |
| Operating and financing lease liabilities, noncurrent | 1,307 | 1,690 | - | - |
| Contingent consideration liabilities, noncurrent | 37,806 | 43,455 | 43,944 | 40,933 |
| Total liabilities | 51,118 | 57,220 | 53,133 | 49,419 |
| Preferred stock, no par value, 5,000 shares authorized no shares issued and outstanding | 0 | 0 | - | 0 |
| Common stock, no par value, 230,000 shares authorized 32,286 and 28,683 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively | 394,289 | 369,211 | 368,524 | 367,965 |
| Accumulated other comprehensive income | 71 | 86 | 86 | 85 |
| Accumulated deficit | -405,051 | -400,761 | -377,806 | -366,952 |
| Total shareholders' deficit | -10,691 | -31,464 | -9,196 | 1,098 |
| Total liabilities and shareholders' deficit | 40,427 | 25,756 | 43,937 | 50,517 |
Insight Molecular Diagnostics Inc. (IMDX)
Insight Molecular Diagnostics Inc. (IMDX)